Characterization of [3H]quisqualate binding to recombinant rat metabotropic glutamate 1a and 5a receptors and to rat and human brain sections

被引:57
作者
Mutel, V
Ellis, GJ
Adam, G
Chaboz, S
Nilly, A
Messer, J
Bleuel, Z
Metzler, V
Malherbe, P
Schlaeger, EJ
Roughley, BS
Faull, RLM
Richards, JG
机构
[1] F Hoffmann La Roche & Co Ltd, Preclin CNS Res, Div Pharma, CH-4070 Basel, Switzerland
[2] Amersham Pharm Biotech, Cardiff Labs, Cardiff, S Glam, Wales
[3] Univ Auckland, Fac Med & Hlth Sci, Dept Anat & Radiol, Auckland 1, New Zealand
关键词
H-3]quisqualate binding; Metabotropic glutamate 1a and 5a receptors; radioautography;
D O I
10.1046/j.1471-4159.2000.0752590.x
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
We have investigated the binding properties of [H-3]quisqualate to rat metabotropic glutamate (mGlu) 1a and 5a receptors and to rat and human brain sections. Saturation isotherms gave K-D values of 27 +/- 4 and 81 +/- 22 nM for mGlu1a and mGlu5a receptors, respectively. Several compounds inhibited the binding to mGlu1a and mGlu5a receptors concentration-dependently. (S)-4-Carboxyphenylglycine, (S)-4-carboxy-3-hydroxyphenylglycine, and (R,S)-1-aminoindan-1,5-dicarboxylic acid, which completely inhibited [H-3]quisqualate binding to the mGlu5a receptor, were inactive in a functional assay using this receptor. The distribution and abundance of binding sites in rat and human brain sections were studied by quantitative receptor radioautography and image analysis. Using 10 nM [H-3]quisqualate, a high density of binding was detected in various brain regions with the following rank order of increasing levels: medulla, thalamus, olfactory bulb, cerebral cortex, spinal cord dorsal horn, olfactory tubercle, dentate gyrus molecular layer, CA1-3 oriens layer of hippocampus, striatum, and cerebellar molecular layer. The ionotropic component of this binding could be inhibited by 30 muM kainate, revealing the distribution of mGlu1+5 receptors. The latter were almost completely inhibited by the group I agonist (S)-3,5-dihydroxyphenylglycine. The binding profile correlated well with the cellular sites of synthesis and regional expression of the respective group I receptor proteins revealed by in situ hybridization histochemistry and immunohistochemistry, respectively.
引用
收藏
页码:2590 / 2601
页数:12
相关论文
共 39 条
[1]  
ABE T, 1992, J BIOL CHEM, V267, P13361
[2]   REDUCED HIPPOCAMPAL LONG-TERM POTENTIATION AND CONTEXT-SPECIFIC DEFICIT IN ASSOCIATIVE LEARNING IN MGLUR1 MUTANT MICE [J].
AIBA, A ;
CHEN, C ;
HERRUP, K ;
ROSENMUND, C ;
STEVENS, CF ;
TONEGAWA, S .
CELL, 1994, 79 (02) :365-375
[3]   SIGNAL TRANSDUCTION AND PHARMACOLOGICAL CHARACTERISTICS OF A METABOTROPIC GLUTAMATE RECEPTOR, MGLUR1, IN TRANSFECTED CHO CELLS [J].
ARAMORI, I ;
NAKANISHI, S .
NEURON, 1992, 8 (04) :757-765
[4]  
Blumcke I, 1996, BRAIN RES, V736, P217
[5]   Group I metabotropic glutamate receptors: Implications for brain diseases [J].
Bordi, F ;
Ugolini, A .
PROGRESS IN NEUROBIOLOGY, 1999, 59 (01) :55-79
[6]   PHENYLGLYCINE DERIVATIVES DISCRIMINATE BETWEEN MGLUR1-MEDIATED AND MGLUR5-MEDIATED RESPONSES [J].
BRABET, I ;
MARY, S ;
BOCKAERT, J ;
PIN, JP .
NEUROPHARMACOLOGY, 1995, 34 (08) :895-903
[7]   Characterization of [3H]-(2S,2′R,3′R)-2-(2′,3′-dicarboxycyclopropyl)glycine ([3H]-DCG IV) binding to metabotropic mGlu2 receptor-transfected cell membranes [J].
Cartmell, J ;
Adam, G ;
Chaboz, S ;
Henningsen, R ;
Kemp, JA ;
Klingelschmidt, A ;
Metzler, V ;
Monsma, F ;
Schaffhauser, H ;
Wichmann, J ;
Mutel, V .
BRITISH JOURNAL OF PHARMACOLOGY, 1998, 123 (03) :497-504
[8]  
CHENG Y, 1973, BIOCHEM PHARMACOL, V22, P3099
[9]   MOTOR DEFICIT AND IMPAIRMENT OF SYNAPTIC PLASTICITY IN MICE LACKING MGLUR1 [J].
CONQUET, F ;
BASHIR, ZI ;
DAVIES, CH ;
DANIEL, H ;
FERRAGUTI, F ;
BORDI, F ;
FRANZBACON, K ;
REGGIANI, A ;
MATARESE, V ;
CONDE, F ;
COLLINGRIDGE, GL ;
CREPEL, F .
NATURE, 1994, 372 (6503) :237-243
[10]   2-methyl-6-(phenylethynyl)-pyridine (MPEP), a potent, selective and systemically active mGlu5 receptor antagonist [J].
Gasparini, F ;
Lingenhöhl, K ;
Stoehr, N ;
Flor, PJ ;
Heinrich, M ;
Vranesic, I ;
Biollaz, M ;
Allgeier, H ;
Heckendorn, R ;
Urwyler, S ;
Varney, MA ;
Johnson, EC ;
Hess, SD ;
Rao, SP ;
Sacaan, AI ;
Santori, EM ;
Veliçelebi, G ;
Kuhn, R .
NEUROPHARMACOLOGY, 1999, 38 (10) :1493-1503